{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:52:09Z","timestamp":1760550729185,"version":"3.37.3"},"reference-count":53,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T00:00:00Z","timestamp":1545350400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0209299","type":"journal-article","created":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T18:43:18Z","timestamp":1545417798000},"page":"e0209299","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan"],"prefix":"10.1371","volume":"13","author":[{"given":"Chen-Hua","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Jen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tung-Hung","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-Chih","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Ming","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tai-Chung","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Jer","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ding-Shinn","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2442-7952","authenticated-orcid":true,"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2018,12,21]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jfma.2015.06.012","article-title":"Hepatitis C virus infection in Taiwan: Past, present, and future","volume":"115","author":"JH Kao","year":"2016","journal-title":"J Formos Med Assoc"},{"key":"ref3","first-page":"2051","article-title":"Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa","volume":"9","author":"CH Liu","year":"2014","journal-title":"Int J Nanomedicine"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/infdis\/jis385","article-title":"Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study","volume":"206","author":"MH Lee","year":"2012","journal-title":"J Infect Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"AJ van der Meer","year":"2012","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","article-title":"Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies","volume":"158","author":"RL Morgan","year":"2013","journal-title":"Ann Intern Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/gutjnl-2014-308163","article-title":"Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection","volume":"64","author":"YC Hsu","year":"2015","journal-title":"Gut"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/gutjnl-2017-313983","article-title":"The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection","volume":"67","author":"P Mahale","year":"2018","journal-title":"Gut"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"JP Messina","year":"2015","journal-title":"Hepatology"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/jmv.23661","article-title":"Clinical and epidemiological features of hepatitis C virus infection in South Korea: a prospective, multicenter cohort study","volume":"85","author":"MH Seong","year":"2013","journal-title":"J Med Virol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1200\/JCO.2010.29.1500","article-title":"Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study","volume":"28","author":"MH Lee","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s40265-014-0247-z","article-title":"Sofosbuvir: a review of its use in patients with chronic hepatitis C","volume":"74","author":"GM Keating","year":"2014","journal-title":"Drugs"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"N Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"N Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"KV Kowdley","year":"2014","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/hep.27890","article-title":"Safety and tolerability of ledipasvir\/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials","volume":"62","author":"SA Alqahtani","year":"2015","journal-title":"Hepatology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa1501315","article-title":"Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1","volume":"373","author":"S Naggie","year":"2015","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","article-title":"Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease","volume":"149","author":"M Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(16)00052-9","article-title":"Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial","volume":"16","author":"M Manns","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.7326\/M16-1205","article-title":"Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial","volume":"166","author":"M Colombo","year":"2017","journal-title":"Ann Intern Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/cid\/cix787","article-title":"Sofosbuvir-based interferon-free direct acting antiviral regimens for heart transplant recipients with chronic hepatitis C virus infection","volume":"66","author":"CH Liu","year":"2018","journal-title":"Clin Infect Dis"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1053\/j.gastro.2016.08.004","article-title":"Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response","volume":"151","author":"NA Terrault","year":"2016","journal-title":"Gastroenterology"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1053\/j.gastro.2016.05.049","article-title":"Effectiveness of sofosbuvir, ledipasvir\/sofosbuvir, or paritaprevir\/ritonavir\/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the Veterans Affairs National Health Care System","volume":"151","author":"GN Ioannou","year":"2016","journal-title":"Gastroenterology"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/hep.28625","article-title":"Real-world effectiveness of ledipasvir\/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients","volume":"64","author":"LI Backus","year":"2016","journal-title":"Hepatology"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jhep.2017.01.028","article-title":"Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: results from a Spanish real-world cohort","volume":"66","author":"JL Calleja","year":"2017","journal-title":"J Hepatol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/apt.14507","article-title":"Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia","volume":"47","author":"F Ji","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jhep.2013.11.003","article-title":"EASL Clinical Practice Guidelines: management of hepatitis C virus infection","volume":"60","year":"2014","journal-title":"J Hepatol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s12072-016-9717-6","article-title":"APASL consensus statements and recommendation on treatment of hepatitis C","volume":"10","author":"M Omata","year":"2016","journal-title":"Hepatol Int"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1128\/JCM.03548-14","article-title":"Comparison of Abbott RealTime HCV Genotype II with Versant Line Probe Assay 2.0 for hepatitis C virus genotyping","volume":"53","author":"CH Liu","year":"2015","journal-title":"J Clin Microbiol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/jgh.13834","article-title":"A noninvasive diagnosis of hepatic fibrosis by BioFibroScore in chronic hepatitis C patients","volume":"33","author":"CH Liu","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1111\/apt.14647","article-title":"Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection","volume":"47","author":"CH Liu","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"17410","DOI":"10.1038\/srep17410","article-title":"Peginterferon plus ribavirin for HIV-infected patients with treatment-na\u00efve acute or chronic HCV infection in Taiwan: a prospective cohort study","volume":"5","author":"CH Liu","year":"2015","journal-title":"Sci Rep"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"ofx028","DOI":"10.1093\/ofid\/ofx028","article-title":"Hepatitis B virus reactivation in patients receiving interferon-free direct-acting antiviral agents for chronic hepatitis C virus infection","volume":"4","author":"CH Liu","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"NA Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/jgh.13912","article-title":"Real-world effectiveness and safety of paritaprevir\/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan","volume":"33","author":"CH Liu","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/apt.15011","article-title":"Comorbidities, concomitant medications, and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan","volume":"48","author":"CH Liu","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"13699","DOI":"10.1038\/s41598-018-32060-7","article-title":"Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study","volume":"8","author":"CH Liu","year":"2018","journal-title":"Sci Rep"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1053\/j.gastro.2017.11.011","article-title":"Efficacy of ledipasvir and sofosbuvir treatment of HCV infection in patients coinfected with HBV","volume":"154","author":"CJ Liu","year":"2018","journal-title":"Gastroenterology"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jhep.2016.04.006","article-title":"Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens","volume":"65","author":"B Maasoumy","year":"2016","journal-title":"J Hepatol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/apt.14478","article-title":"Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor","volume":"47","author":"S Fourati","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1111\/liv.12861","article-title":"Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy","volume":"35","author":"SH Al Marzooqi","year":"2015","journal-title":"Liver Int"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1053\/j.gastro.2015.03.004","article-title":"Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function","volume":"149","author":"E Serti","year":"2015","journal-title":"Gastroenterology"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1136\/gutjnl-2015-310033","article-title":"Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFN\u03b1","volume":"66","author":"E Serti","year":"2017","journal-title":"Gut"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"MP Curry","year":"2015","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jhep.2017.01.007","article-title":"NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome","volume":"66","author":"S Zeuzem","year":"2017","journal-title":"J Hepatol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/liv.13203","article-title":"Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature","volume":"36","author":"R D\u2019Ambrosio","year":"2016","journal-title":"Liver Int"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/hep.29005","article-title":"Eight weeks of ledipasvir\/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection","volume":"65","author":"KV Kowdley","year":"2017","journal-title":"Hepatology"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hep.27826","article-title":"Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis","volume":"62","author":"KR Reddy","year":"2015","journal-title":"Hepatology"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1473-3099(15)70099-X","article-title":"Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial","volume":"15","author":"M Mizokami","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/jgh.13305","article-title":"Ledipasvir\/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus","volume":"31","author":"WL Chuang","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S2468-1253(18)30002-5","article-title":"Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis","volume":"3","author":"MM M\u00fccke","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jcv.2017.03.007","article-title":"Evaluation of the Abbott RealTime HCV genotype II plus RUO (PLUS) assay with reference to core and NS5B sequencing","volume":"90","author":"MA Mallory","year":"2017","journal-title":"J Clin Virol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0209299","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T04:00:01Z","timestamp":1605758401000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0209299"}},"subtitle":[],"editor":[{"given":"Tatsuo","family":"Kanda","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,12,21]]},"references-count":53,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,12,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0209299","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2018,12,21]]}}}